By Mary Vanac
CLEVELAND, Ohio — Case Western Reserve University licensed the right to make and sell three types of neuromodulation electrodes and a control unit to Ardiem Medical Inc.
Neurological
Welcome to MassDevice's Neurological Hub, your resource for the latest news in the neurological device space. Stay informed about the innovations and business news shaping the neurological industry.
🧠 Narrow your focus with these categories:
Neuromodulation/Neurostimulation | Bioelectronic Medicine | Pain Management | Brain-Computer Interfaces
Here are the top neurological device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ 7 neurotech companies you need to know
+ Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
+ 7 brain-computer interface companies you need to know
+ Natalizumab and PML: The complex dance of benefit and risk for MS
Latest Neurological News
Cyberonics’ Q3 sales rise, net falls
Cyberonics Inc. (NSDQ:CYBX) posted third-quarter sales of $40.8 million for the three months ended Jan. 22, up 15.8 percent compared with $35.3 million during the same period in 2009. Net income fell 9.7 percent to $8.8 million, compared with $9.8 million during Q3 2009:
Press Release
Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2010 Third Quarter
– Company Achieves Sales Growth of 16% –
– Increases Sales and Operating Income Guidance –
NeuroTherm hits the acquisitions trail again
NeuroTherm Inc. added to its portfolio of pain management technologies with the acquisition of some of a European company’s needle lines.
The Wilmington, Mass.-based medical device maker paid an undisclosed amount for Dutch firm Technomed Europe’s intellectual property and manufacturing know-how "associated with certain needle product lines," according to a press release.
NeuroTherm bought Micron Catheter last summer for an undisclosed amount, adding the Palm Beach gardens, Fla.-based company’s epidural scar removal catheter to its holdings.
NeuroMetrix swings to Q4 black on warrants revaluation
A revaluation of warrants and a change in reimbursement policy helped produce fourth-quarter profits and hope for future top-line growth for NeuroMetrix Inc. (NSDQ:NURO).
Micrus Endovascular swings to black ink during Q3
Micrus Endovascular Corp. (NSDQ:MEND) posted third-quarter sales of $22.8 million for the three months ended Dec. 31, 2009, up 24.4 percent compared with $18.3 million during the same period in 2008. The company swung from a net loss of $2.3 million during Q3 2009 to net income of $3.3 million during Q3 2010:
Press Release
Micrus Endovascular Reports Fiscal Third Quarter Revenues of $22.8 Million and Diluted EPS of $0.20
Record Quarterly Revenues up 24%; Double-digit Revenue Growth in All Major Geographic Regions; Fourth Consecutive Quarter of Profitability
FDA sets panel date for Medtronic’s DBS epilepsy device
Medical devices giant Medtronic Inc. (NYSE: MDT) will go before a Food & Drug Administration panel in early March to seek pre-market approval for its deep-brain stimulator for epilepsy.
The Center for Devices and Radiological Health set a March 12 date for its panel to discuss the company’s implantable device, which stimulates the left and right anterior nucleus of the thalamus to reduce seizures.
Mayo Clinic develops deep-brain stimulation system
By Thomas Lee
ROCHESTER, Minnesota – The pacemaker and implantable cardioverter defibrillator revolutionized heart medicine (and gave birth to a multi-billion dollar global industry) by successfully blending detection and therapy into a single, “smart” device. The technology notices a faulty heart beat and automatically delivers an electric shock to correct it.
Synapse Biomedical aims to raise $1.2 million in Series C round
By Mary Vanac
OBERLIN, Ohio — Synapse Biomedical Inc. raised more than $433,000 from investors on its way to $1.2 million to repay debt and get ready to supply its diaphragm pacing technology to a new market: ALS patients.
Somanetics posts Q4 sales increase, earnings plunge
Somanetics Corp. (NSDQ:SMTS) posted fourth-quarter sales of $14.5 million for the three months ended Nov. 30, 2009, up 6.3 percent compared with $13.7 million during the same period during fiscal 2008. Net income fell 54.5 percent to $1.5 million, compared with $3.3 million during Q4 2008:
St. Jude Medical wins Japanese approval for spinal cord stimulation system
St. Paul, Minnesota —St. Jude Medical Inc. (NYSE:STJ) won Japanese regulatory approval to begin selling a spinal-cord stimulation system for patients suffering from chronic pain.
Boston Scientific enrolls 630th patient in brain aneurysm coiling trial
Boston Scientific Corp. (NYSE:BSX) enrolled the 630th and final patient in its MAPS clinical trial comparing treatment of brain aneurysms with bare-metal and biopolymer-coated coils.
The study, which the Natick, Mass.-based medical device giant began in 2007, aims to measure how often aneurysms recur one year after being treated with its bare-platinum GDC and biopolymer-coated Matrix2 detachable coils.
